| __timestamp | BioCryst Pharmaceuticals, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 9335772 |
| Thursday, January 1, 2015 | 1896000 | 999000 |
| Friday, January 1, 2016 | 2699000 | 978000 |
| Sunday, January 1, 2017 | 1702000 | 952000 |
| Monday, January 1, 2018 | 471000 | 956000 |
| Tuesday, January 1, 2019 | 4101000 | 8122999 |
| Wednesday, January 1, 2020 | 1676000 | 8712000 |
| Friday, January 1, 2021 | 7264000 | 13980000 |
| Saturday, January 1, 2022 | 6594000 | 21135000 |
| Sunday, January 1, 2023 | 4661000 | 10755000 |
Unlocking the unknown
In the ever-evolving landscape of biotechnology, understanding cost structures is crucial. This chart offers a fascinating glimpse into the cost of revenue trends for Iovance Biotherapeutics, Inc. and BioCryst Pharmaceuticals, Inc. over the past decade.
From 2014 to 2023, Iovance Biotherapeutics has seen a dramatic increase in its cost of revenue, peaking in 2022 with a staggering 2,113% rise from its 2014 figures. In contrast, BioCryst Pharmaceuticals experienced a more modest growth, with its highest cost of revenue in 2021, marking a 5,855% increase from 2014.
These trends highlight the differing financial strategies and market challenges faced by these companies. Iovance's significant cost increase may reflect aggressive R&D investments, while BioCryst's steadier growth suggests a more conservative approach. Understanding these dynamics is key for investors and industry analysts alike.
Amgen Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for GSK plc and Iovance Biotherapeutics, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down BeiGene, Ltd. and Iovance Biotherapeutics, Inc.'s Expenses
Cost of Revenue Comparison: Catalent, Inc. vs Iovance Biotherapeutics, Inc.
Comparing Cost of Revenue Efficiency: Exelixis, Inc. vs Iovance Biotherapeutics, Inc.
Cost of Revenue Trends: Halozyme Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Lantheus Holdings, Inc. vs BioCryst Pharmaceuticals, Inc.
Analyzing Cost of Revenue: CRISPR Therapeutics AG and Iovance Biotherapeutics, Inc.
Cost of Revenue: Key Insights for Xenon Pharmaceuticals Inc. and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Iovance Biotherapeutics, Inc. vs BioCryst Pharmaceuticals, Inc. Trends and Insights